8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 19, 2016)

Filed July 19, 2016For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on July 19, 2016, primarily to report its financial results for the second quarter ended July 3, 2016. The filing includes a press release detailing sales and earnings, along with supplementary sales data and condensed consolidated statements of earnings. While the filing itself is procedural, it signals the release of JNJ's quarterly performance figures, which are critical for investors to assess the company's operational success, revenue growth, and profitability trends. Investors should refer to the attached press release and financial statements for detailed insights into JNJ's performance across its various business segments. Key metrics to monitor would include reported sales figures, earnings per share (EPS), and any commentary provided by management regarding factors influencing these results, such as market conditions, new product introductions, and competitive dynamics. This information is essential for understanding the company's current financial health and its outlook for the remainder of the fiscal year.

Key Highlights

  • 1Johnson & Johnson reported its financial results for the second quarter ended July 3, 2016, via an 8-K filing.
  • 2The filing includes a press release announcing Q2 sales and earnings.
  • 3Unaudited comparative supplementary sales data is provided.
  • 4Condensed Consolidated Statements of Earnings for the second quarter are included.
  • 5The event date for the reported financial information was July 18, 2016.
  • 6The filing serves as the official mechanism to disseminate Q2 financial performance to the public.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially announce and provide details on Johnson & Johnson's financial results for the second quarter ended July 3, 2016, including sales and earnings.

The detailed financial results are contained within the attached press release (Exhibit 99.15) and the Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the second quarter (Exhibit 99.20).

Investors should look for key metrics such as total sales, sales by segment (e.g., Pharmaceuticals, Medical Devices, Consumer Health), earnings per share (EPS), net income, and any management commentary on performance drivers and future outlook.

No, this particular 8-K filing is specifically for reporting quarterly financial results. While financial performance can reflect business changes, this filing's main content is the Q2 sales and earnings data.